Hematology Department, University Hospital, Institute of Biomedical Research of Salamanca (IBSAL), University Hospital of Salamanca, 37007 Salamanca, Spain.
Cancer Research Center-IBMCC (USAL-CSIC), Salamanca, Spain.
Cells. 2021 Feb 5;10(2):336. doi: 10.3390/cells10020336.
Some genetic abnormalities of multiple myeloma (MM) detected more than two decades ago remain major prognostic factors. In recent years, the introduction of cutting-edge genomic methodologies has enabled the extensive deciphering of genomic events in MM. Although none of the alterations newly discovered have significantly improved the stratification of the outcome of patients with MM, some of them, point mutations in particular, are promising targets for the development of personalized medicine. This review summarizes the main genetic abnormalities described in MM together with their prognostic impact, and the therapeutic approaches potentially aimed at abrogating the undesirable pathogenic effect of each alteration.
二十多年前发现的多发性骨髓瘤(MM)的一些遗传异常仍然是主要的预后因素。近年来,先进的基因组方法学的引入使得对 MM 中的基因组事件进行了广泛的解读。尽管新发现的改变中没有一个显著改善了 MM 患者的预后分层,但其中一些改变,特别是点突变,为个性化医学的发展提供了有前途的靶点。这篇综述总结了 MM 中描述的主要遗传异常及其对预后的影响,以及可能旨在消除每种改变的不良致病效应的治疗方法。